Bentley: Juul Exit Threatens Progress in Harm Reduction

Industry Insight by tobaccoreporter
Jul.01.2022
The Food and Drug Administration’s order to remove Juul products from the U.S. market threatens progress in tobacco harm reduction, according to Guy Bentley, director of consumer freedom at the Reason Foundation.

Writing on the foundation’s website, Bentley reminds his audience that e-cigarettes are not only less harmful than their combustible counterparts, but they are also more effective in helping smokers quit than FDA-approved therapies such as nicotine gum and patches.

Bentley: Juul Exit Threatens Progress in Harm Reduction

The FDA, he writes, acknowledged as much when it authorized Vuse e-cigarettes in 2021 and claims it recognizes the role these safer nicotine alternatives can play in reducing smoking.

 

If the Juul order is implemented, says Bentley, many Juul users will likely return to smoking, while a portion of smokers who would have transitioned to Juul will continue to light up.

Bentley: Juul Exit Threatens Progress in Harm Reduction

Bentley says the FDA Juul denial makes a mockery of the claim that it’s evaluating science in the best interests of public health. A study published in the New England Journal of Medicine found e-cigarettes to be twice as effective as traditional nicotine replacement therapies.

 

According to Bentley, the decision also punctures a hole in the logic of the FDA’s recently announced policy to reduce nicotine levels in cigarettes to minimally or non-addictive levels. Without an acceptable legal alternative, smokers may simply smoke more cigarettes to get their nicotine fix.

 

“By banning the most popular e-cigarette among adults, the agency’s commitment to transitioning smokers to safer alternatives rings hollow,” writes Bentley.

AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s Shisha Brand Al Fakher Launches New Pod-Based Vape in Germany, Touting Non-Ceramic Atomization Technology
AIR’s shisha brand Al Fakher has launched its rechargeable pod-based vape Crown Switch in Germany, featuring Coldstream technology and claiming low-temperature vaporization without ceramic or metal heating elements. The device is now available on shisha-world, while AIR is simultaneously pushing ahead with its plan to go public on Nasdaq via a SPAC merger.
Nov.20 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
ZYN Nicotine Pouches Seek MRTP Authorization; FDA Sets January Meeting
The U.S. FDA has scheduled a Tobacco Products Scientific Advisory Committee (TPSAC) meeting for January 22, 2026, to review Swedish Match USA’s Modified Risk Tobacco Product (MRTP) applications for 20 ZYN nicotine pouch products. Although the products gained PMTA authorization in early 2025, MRTP approval is required for marketing them with reduced-risk claims.
Nov.24 by 2FIRSTS.ai
Philip Morris Korea: IQOS ILUMA i “SELETTI” Limited Edition Sells Out in One Week; Prime Model Sells Out on Launch Day
Philip Morris Korea: IQOS ILUMA i “SELETTI” Limited Edition Sells Out in One Week; Prime Model Sells Out on Launch Day
Philip Morris Korea and Italian design brand SELETTI’s limited “IQOS ILUMA i × SELETTI” collection sold out within one week of launch, with the “Prime” model selling out on its first day of release.
Nov.11 by 2FIRSTS.ai
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Over 92,000 kg of Nicotine Products Seized at Ambassador Bridge
Over 92,000 kg of Nicotine Products Seized at Ambassador Bridge
The Canada Border Services Agency seized 92,270 kilograms of undeclared nicotine products at the Ambassador Bridge over four days, according to a social media post. The confiscated items included vapes, tins, and pouches. Officials stated the seizure helps prevent profits from reaching organized crime groups.
Dec.03 by 2FIRSTS.ai